[go: up one dir, main page]

WO2025232973A1 - Mélange minéral contenant de la clinoptilolite ou clinoptilolite destiné à être utilisé en tant que pansement pour plaie minéral - Google Patents

Mélange minéral contenant de la clinoptilolite ou clinoptilolite destiné à être utilisé en tant que pansement pour plaie minéral

Info

Publication number
WO2025232973A1
WO2025232973A1 PCT/EP2024/062770 EP2024062770W WO2025232973A1 WO 2025232973 A1 WO2025232973 A1 WO 2025232973A1 EP 2024062770 W EP2024062770 W EP 2024062770W WO 2025232973 A1 WO2025232973 A1 WO 2025232973A1
Authority
WO
WIPO (PCT)
Prior art keywords
clinoptilolite
wound
mineral mixture
mineral
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/062770
Other languages
German (de)
English (en)
Inventor
Thomas Görner
B.Sc. Ellen ZIPPER
Hans Wiech
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Froximun AG
Original Assignee
Froximun AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Froximun AG filed Critical Froximun AG
Priority to PCT/EP2024/062770 priority Critical patent/WO2025232973A1/fr
Publication of WO2025232973A1 publication Critical patent/WO2025232973A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the objective of the invention is to improve and simultaneously simplify the treatment of secondarily healing wounds, particularly chronic wounds.
  • the solution to this objective consists of clinoptilolite or a mineral mixture containing clinoptilolite according to claim 1 for use as a mineral wound dressing for the treatment of secondarily healing wounds of the skin and/or underlying tissue, particularly chronic, poorly healing, or non-healing wounds (for example, pressure ulcers, medical foot syndrome, and leg ulcers).
  • the clinoptilolite/the mineral mixture containing clinoptilolite is present in pulverized form or pulverized within a suspension and is applied to the wounds in powder or suspension form to promote wound healing.
  • the naturally occurring zeolite clinoptilolite is used.
  • Clinoptilolite is a crystalline, microporous rock of volcanic origin belonging to the zeolite group. It is grey-green in color and odorless.
  • the basic skeleton of the clinoptilolite crystal lattice consists of SiO2 tetrahedra and Al2O3. The ratio of silicon to aluminum in the tetrahedra is usually 4:1 to 8:1.
  • the microporous structure allows it to bind irritants and pollutants, especially mercury, lead, and cadmium, radionuclides, ammonium, histamine, and other biogenic amines.
  • This property allows clinoptilolite to be applied to wounds, for example, in the case of injured skin, acting as a protective shield where it can accelerate hemostasis and prevent further penetration by microorganisms.
  • powdered clinoptilolite is already used in various fields, including dermatology.
  • clinoptilolite or clinoptilolite-containing mixtures can be used for the absorption or elimination of amines and/or their salts that occur in aqueous suspension in the digestive tract or on the skin of humans and animals.
  • the clinoptilolite is not absorbed through the intestines or skin and therefore has no pharmacokinetic activity.
  • histamine released by microorganisms can be absorbed and eliminated by clinoptilolite.
  • the cleaned wound is repeatedly treated with clinoptilolite or a mixture of clinoptilolite and water and then bandaged with a sterile dressing. Finally, the clinoptilolite can dry and fall off along with a scab.
  • the mineral wound dressing consisting of clinoptilolite or a mineral mixture containing clinoptilolite, is suitable for treating wounds healing by secondary intention, such as those caused by vascular circulatory disorders and wound healing disorders of various origins.
  • the Secondarily healing wounds include, in particular, chronic wounds such as diabetic foot ulcers resulting from diabetic foot syndrome and leg ulcers. Diabetic foot is a complication of diabetes mellitus characterized by poorly healing chronic foot wounds.
  • Clinoptilolite or the mineral mixture containing clinoptilolite, is also suitable for treating secondarily healing wounds resulting from burns and injuries with severed dermis. It can also be used advantageously if the wound(s) are one or more infected and/or acute, malodorous.
  • the clinoptilolite or the mineral mixture containing clinoptilolite can be applied directly to the wound and, if necessary, the surrounding area.
  • the mineral wound dressing formed by the clinoptilolite creates a moist environment due to exposure to moisture beneath the wound, thus becoming a moist wound dressing.
  • This dressing can then remain on the wound for more than a day, similar to a mineral plaster, but can also be easily removed if necessary without damaging the granulation or epithelial tissue, which reduces wound pain.
  • it has proven particularly advantageous and effective to leave the mineral wound dressing on the wound for several days, preferably 3 to 5 days, and only reapply the clinoptilolite to the remaining moist areas as needed.
  • the mineral wound dressing visibly promotes the development of granulation tissue. As a result of granulation, the mineral wound dressing is displaced upwards from the inside of the wound and therefore does not initially need to be removed.
  • the particles of the clinoptilolite powder can have particle sizes with a mean diameter in the range of 8.0 ⁇ m to 12 ⁇ m.
  • An advantageous particle size distribution exhibits: ⁇ a 10th percentile value, below which 10% of all particles are found, in the range of 1.1 ⁇ m to 3.0 ⁇ m; ⁇ a 50th percentile value, below which 50% of all particles are found, in the range of 5.0 ⁇ m to 10 ⁇ m; and ⁇ a 90th percentile value, below which 90% of all particles are found, in the range of 20 ⁇ m to 26 ⁇ m.
  • the particles of a comminuted clinoptilolite/clinoptilolite-containing mineral mixture, intended for use in a suspension can have particle sizes with a mean diameter in the range of 1.5 ⁇ m to 2.5 ⁇ m.
  • a particle size distribution is preferably characterized by: ⁇ a 10th percentile value, below which 10% of all particles are found, in the range of 0.5 ⁇ m to 1.0 ⁇ m; ⁇ a 50th percentile value, below which 50% of all particles are found, in the range of 1.5 ⁇ m to 2.5 ⁇ m; and ⁇ a 90th percentile value, below which 90% of all particles are found, in the range of 3.0 ⁇ m to 4 ⁇ m.
  • Fig. 1 A bar chart comparing the total wound area of patient group B receiving standard wound treatment to the total wound area of patient group A treated with clinoptilolite at specific monitoring days within an observation period, with the total area values expressed as percentages relative to a baseline of 100%.
  • Fig. 2A A photograph of a patient's chronic leg ulcer (ulcus cruris) on the left lower leg at the time of admission for treatment.
  • Fig. 2B A photograph of the same patient's wound after four weeks of treatment with micronized clinoptilolite.
  • Fig. 1 A bar chart comparing the total wound area of patient group B receiving standard wound treatment to the total wound area of patient group A treated with clinoptilolite at specific monitoring days within an observation period, with the total area values expressed as percentages relative to a baseline of 100%.
  • Fig. 2A A photograph of a patient's chronic leg ulcer (ulcus cruris) on the left lower leg at the time of admission for treatment.
  • Fig. 2B A photograph of the same patient'
  • FIG. 3A A photograph of a patient's chronic leg ulcer (ulcus cruris) on the right leg due to varicose vein disease (ulcus cruris varicosum) at the time of admission for treatment.
  • Fig. 3B A photograph of the same patient's wound after four weeks of treatment with micronized clinoptilolite
  • Fig. 4A a photographic image of a chronic wound of a patient with a leg ulcer on the left lower leg at the time of the procedure for treatment
  • Fig. 4B a photographic image of the patient's wound after four weeks of treatment with micronized clinoptilolite
  • Fig. 5A A photographic image of a chronic wound of a patient with a leg ulcer at the time of admission for treatment;
  • Fig. 5A A photographic image of a chronic wound of a patient with a leg ulcer at the time of admission for treatment; Fig.
  • FIG. 5B A photographic image of the patient's wound after four weeks of standard wound care
  • Fig. 6A A photographic image of a chronic wound of a patient with a leg ulcer on the left calf at the time of admission for treatment
  • Fig. 6B A photographic image of the patient's wound after four weeks of standard wound care
  • Fig. 7A A photographic image of a chronic wound of a patient with a leg ulcer on the right lower leg at the time of admission for standard wound care
  • Fig. 7B A photographic image of the patient's wound after four weeks of standard wound care.
  • Wound healing findings should be documented photographically and examined using bacterial cultures from the wound swab.
  • the randomized, controlled trial was conducted with 50 patients, 19 female and 31 male. According to predefined inclusion criteria, the patients presented with chronic wounds, some of which had been present for many months or years, for example, in association with diabetic foot syndrome and other vascular circulatory disorders of various origins.
  • a significantly faster reduction in wound area was observed under treatment with clinoptilolite powder, regardless of the underlying disease. This was accompanied by a significant reduction in inflammation/redness of the wound and surrounding skin, and was also reflected in faster granulation of the wounds.
  • clinoptilolite powder When using clinoptilolite powder, a reduction in fibrin deposits and an increase in epithelialization were observed compared to conventional treatment. Furthermore, the clinoptilolite powder, when used as a wound powder, had a positive effect on the wound's moisture environment, thus supporting exudate management during wound care. No adverse side effects occurred during treatment with the clinoptilolite powder, and its tolerability as a skin powder was very good. In addition, patients treated with the clinoptilolite powder no longer exhibited an unpleasant wound odor. The therapy was perceived as painless by the patients. For the study, an activated, natural clinoptilolite modified by a comminution or micronization process described below was used.
  • the pH of the aqueous supernatant in a clinoptilolite suspension in water is approximately pH 7.
  • Clinoptilolite solids are hygroscopic. Different clinoptilolite products vary in their particle size distribution achieved through micronization. Particle size is determined by laser diffractometry and serves as product control to ensure that the respective products meet the required specifications. Table 1 shows the particle size distribution of a clinoptilolite powder for use as a wound powder for secondarily healing wounds.
  • Table 1 Cumulative Values [%] X 10 X 50 X 90 Mean Diameter Particle Size [ ⁇ m] 1.1-3.0 5.0-10.0 20.0-26.0 8.0-12.0
  • Table 2 shows the particle size distribution of a comminuted clinoptilolite material intended for use in a suspension for the treatment of secondarily healing wounds.
  • Table 2 Cumulative Values [%] X10 X50 X90 Mean Diameter Particle Size [ ⁇ m] 0.5-1.0 1.5-2.5 3.0-4.0 1.5-2.5
  • the clinoptilolite used regardless of the degree of comminution or micronization, is a dry, non-greasy, mineral substance that is not subject to any material changes through degradation or natural, chemical, or biological degradation processes.
  • the clinoptilolite material is not subject to degradation in the form of a loss of material properties, such as material fatigue or chemical decomposition.
  • the crushed or micronized clinoptilolite material contains no organic components and therefore no proteins, fats, carbohydrates, or dietary fiber.
  • the clinoptilolite material contains no enzymes. Consequently, the clinoptilolite material is not subject to biological degradation, which could have an impact on the product and its stability. Details of the Study: The study aimed to investigate the extent to which various characteristics or symptoms of chronic inflammation of a wound of different origins could be influenced by a clinoptilolite powder obtained through the described crushing process.
  • Visit 1 took place between day 1 and day 6 of initial inpatient admission, visit 2 (T2) on day 6 or 7, visit 3 (T3) on day 15 (+/- 2 days), and visit 4 (T4) around day 32 (+/- 2 days).
  • Documentation began with visit 1 (T1), during which patients were assigned to the respective group receiving treatment with or without clinoptilolite powder.
  • the study procedure followed a Clinical Trial Protocol (CIP).
  • Dressing changes were performed at least at visits 2 (T2), 3 (T3), and 4 (T4).
  • swabs were taken to determine bacteriology and assess for possible wound infection, and standard conservative, sterile wound irrigation with Octenisept and isotonic saline solution was performed.
  • Oxygen balance management Oxygen-permeable dressings were used.
  • I – Infection control In addition to routine laboratory diagnostics, antiseptic cleansing and irrigation solutions were used.
  • S – “Support” Supportive measures for wound treatment, such as compression, were administered as needed.
  • T – Tissue management Depending on the situation, debridement, i.e., deep cleaning of the wound, was performed as standard procedure. The aim of the clinical trial was, on the one hand, to demonstrate the clinical efficacy and biological safety of clinoptilolite powder during the treatment of impaired wound healing in patients with chronic wounds, including patients suffering from diabetic foot syndrome, and on the other hand, to investigate a possible influence of clinoptilolite powder on the bacterial environment and the wound healing process.
  • ⁇ severe cardiovascular disease ⁇ other primary chronic skin diseases, ⁇ severe hepatic and/or renal insufficiency, ⁇ severe dementia/delirium, ⁇ septic condition, ⁇ lack of compliance, and ⁇ lack of informed consent.
  • conservative wound care was performed, including daily dressing changes and sterile irrigation of the wound with Octenisept® and isotonic saline solution.
  • the clinoptilolite powder was dosed to ensure uniform wound coverage, regardless of the thickness of the dressing.
  • Administration was performed in the The procedure involved sprinkling the clinoptilolite powder onto the wound after changing the dressing and/or cleaning it, distributing it according to the specified dosage.
  • Group A the treatment group, consisted of 25 patients with chronic wounds and impaired wound healing, particularly those with diabetic foot syndrome, and was treated with clinoptilolite powder.
  • Group B the control group, also consisted of 25 patients with chronic wounds and impaired wound healing, particularly those with diabetic foot syndrome, and received only standard wound care without clinoptilolite powder. Participants were available at all times. All 50 patients were able to undergo outpatient monitoring and the corresponding group-specific treatment at each scheduled appointment (T1 to T4). All patients in Group A were treated with the same batch of clinoptilolite powder.
  • the study's objective was to demonstrate the clinical efficacy and biosafety of clinoptilolite powder during the treatment of impaired wound healing in patients with chronic wounds, including wounds resulting from diabetic foot syndrome.
  • the study aimed to determine whether clinoptilolite powder had a positive effect on the wound healing process in this condition.
  • the data presented below demonstrate that the primary endpoint was met and the interventions were successful.
  • the primary endpoints were defined as measurable, assessable, and clearly defined parameters: wound area size, inflammatory status, and the visual development of the wound and surrounding tissue.
  • Table 3 The clinical verbal assessment of the wounds treated in the study for all included patients is shown in Table 3, which reports on the wound characteristics at each examination time point T1 to T4 based on the listed assessment parameters.
  • Table 4 Total area T1 T2 T3 T4 in mm2 Area 68805 38962 32443 17728 Group A Area 26986 20075 21033 17952 Group B Total area T1 T2 T3 T4 in mm2 Percent 100 67 60 33 Area Group A Percent 100 73 65 55 Area Group B
  • Figure 1 shows the values, expressed as percentages, of the total wound areas of Group B (treated with standard wound care) and Group A (treated with clinoptilolite) at monitoring days T1, T2, T3, and T4 of the observation period, as shown in a bar chart. The standard deviation around the mean is also shown, with a corresponding 95% confidence interval.
  • SoC standard wound treatment
  • FIGS. 2A to 7B show an excerpt from the photographic documentation of treatment with and without clinoptilolite powder (MANC). This provides visual support for the results mentioned above. Three patients from each treatment group A and treatment group B are shown at the time of admission for treatment (T0) and after four weeks of treatment (T4).
  • FIGS. 2A and 2B are of a patient in group A who, at the time of admission for treatment, was 74 years old, weighed 77 kg, and had a BMI of 27.61 (Battery Mass Index, which relates body weight to height in meters squared). Underlying medical conditions include hypothyroidism (overactive thyroid), protein V deficiency, and acute lumbar spine syndrome. Initial findings include diabetes mellitus and high blood pressure (hypertension), while neither chronic kidney disease (CKD) nor liver disease was detected. The patient was a non-smoker. She presented with bilateral wounds on her right lower leg, classified as mixed leg ulcers. A leg ulcer is a chronic wound.
  • FIG. 2A shows the leg ulcer on the left lower leg at the time of the initial treatment, with a wound area of 4311 mm2 .
  • the image in Fig. 2A shows the leg ulcer on the left lower leg at the time of the initial treatment, with a wound area of 4311 mm2 .
  • the image in Fig. 2A shows the leg ulcer on the left lower leg at the time of the initial treatment, with a wound area of 4311 mm2 .
  • FIG. 2B shows the wound at time point (T4) after the fourth week of treatment with clinoptilolite powder, revealing a significantly reduced wound area of only 2466 mm2 . Furthermore, the redness has decreased, making the wound and surrounding area appear lighter in the black and white image, and smooth wound edges have formed.
  • the photographs in Figs. 3A and 3B are from a patient in group A who, at the time of the initial treatment, was 36 years old, weighed 109 kg, and had a BMI of 28.67. Underlying conditions include varicose leg ulcers (ulcus cruris varicosum) and asthma. In this patient, the initial findings regarding diabetes mellitus, hypertension, liver disease, and chronic kidney disease (CKD) were all negative. The patient was a smoker.
  • CKD chronic kidney disease
  • the photograph in Fig. 3A shows the leg ulcer on the right leg in the region of the medial malleolus, also known as the inner malleolus or tibial malleolus, at the time of the initial treatment, with the wound area measuring 3090 mm2 .
  • the image in Fig. 3B shows the wound after week 4 (T4) of treatment with clinoptilolite powder, in which case the wound area was reduced by approximately four-fifths to only 578 mm2 .
  • the photographs in Figs. 4A and 4B are of a patient in group A who, at the time of the initial treatment, was 76 years old, weighed 75 kg, and had a BMI of 29.30.
  • Her underlying medical conditions include diabetes, hypertension, and chronic kidney disease (CKD).
  • CKD chronic kidney disease
  • the patient was a smoker.
  • the photograph in Fig. 4A shows a leg ulcer on the patient's left lower leg at the time of admission for treatment, with a wound area of 11,585 mm2 at that time.
  • the image in Fig. 4B shows the wound after week 4 (T4) of treatment with clinoptilolite powder, in which case the wound area had been reduced to only 16.0 mm2 , meaning that the wound had almost completely disappeared.
  • Figures 5A to 7B show a portion of the photographic documentation extract, illustrating the results of standard of care (SoC) group B, i.e., without clinoptilolite powder (MANC).
  • SoC standard of care
  • the photographic images in Figures 5A and 5B are assigned to a patient in group B who, at the time of the photograph being taken for treatment, was 90 years old, weighed 69 kg, and had a BMI of 26.95. Underlying conditions suffered by the patient, which may be causally related to the chronic wound, include hypertension, chronic kidney disease (CKD), and diabetes mellitus (DDM). Accordingly, the initial findings were positive for diabetes mellitus, hypertension, and CKD, while no liver disease was detected.
  • the patient was a smoker.
  • the photograph in Fig. 5A shows the patient's leg ulcer on her left lower leg at the time of admission for treatment, with the wound area measuring 4125 mm2 .
  • FIG. 5B shows the wound after week 4 (T4) of standard wound care (SoC), where there was hardly any improvement and the wound area had even increased to 4375 mm2 .
  • the photographs in Figures 6A and 6B are of a patient in group B who, at the time of admission for treatment, was 73 years old, weighed 58 kg, and had a BMI of 21.56.
  • Her underlying medical conditions included stage IV peripheral arterial disease (PAD) on the left side, coronary artery disease (CAD), and aortic ectasia.
  • CAD coronary artery disease
  • CKD chronic kidney disease
  • Initial examinations were negative for diabetes mellitus and liver disease. The patient was a non-smoker.
  • the photograph in Figure 6A shows a large, multi-layered leg ulcer on the patient's left calf at the time of admission for treatment, with a wound area of 4213 mm2 .
  • the illustration in Fig. 6B shows the multi-part wound at the time after week 4 (T4) of a standard wound treatment (SoC), with the wound area having increased to a total of 4885 mm2 .
  • the photographs in Figures 7A and 7B are of a patient in group B who, at the time of admission for treatment, was 78 years old, weighed 97 kg, and had a BMI of 39.35.
  • Her underlying medical conditions included stage IV peripheral arterial disease (PAD) on the right side, hypothyroidism (overactive thyroid), and hypercholesterolemia.
  • PAD peripheral arterial disease
  • the clinoptilolite powder supported wound drying, caused no pain, and also eliminated unpleasant wound odor.
  • the clinoptilolite powder achieved a faster and greater wound healing effect over the same treatment period than the standard wound treatment in control group B.
  • Clinoptilolite powder demonstrated significantly greater benefit in the healing of critical chronic wounds than conventional wound treatment.
  • the wound depth also decreased many times over with the application of clinoptilolite powder, in parallel with the wound surface area.
  • Clinoptilolite powder absorbs excess exudate and toxic substances more effectively than conventional wound dressings used in standard wound care, as it can absorb both exudate and toxic substances, even under compression bandages.
  • the mineral wound dressing formed by the clinoptilolite powder also helps maintain a moist environment and protects against dehydration.
  • the advantage over conventional wound dressings is that the mineral dressing adheres to the wound like a "second skin” (scab), thus creating an optimal wound healing environment. This "second skin” also prevents bacterial penetration and helps protect against infection. Secondary infections are prevented.
  • the mineral wound dressing visibly promotes the development of granulation tissue. It also apparently promotes angiogenesis.
  • the mineral wound dressing is also easy to remove without damaging the granulation or epithelial tissue, which reduces wound pain.
  • Clinoptilolite powder is therefore suitable as a mineral wound dressing for the treatment of chronic wounds.
  • BMI Body Mass Index body weight in relation to height in meters squared
  • PAD Peripheral arterial disease
  • SoC Conventional wound care, standard wound care

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne la clinoptilolite ou un mélange minéral contenant de la clinoptilolite destiné à être utilisé en tant que pansement pour plaie minéral pour traiter des plaies de cicatrisation secondaire de la peau et/ou d'un tissu sous-jacent, en particulier des plaies chroniques, cicatrisant mal ou ne cicatrisant pas, la clinoptilolite/le mélange minéral contenant de la clinoptilolite étant broyé sous forme de poudre ou broyé dans une suspension.
PCT/EP2024/062770 2024-05-08 2024-05-08 Mélange minéral contenant de la clinoptilolite ou clinoptilolite destiné à être utilisé en tant que pansement pour plaie minéral Pending WO2025232973A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2024/062770 WO2025232973A1 (fr) 2024-05-08 2024-05-08 Mélange minéral contenant de la clinoptilolite ou clinoptilolite destiné à être utilisé en tant que pansement pour plaie minéral

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2024/062770 WO2025232973A1 (fr) 2024-05-08 2024-05-08 Mélange minéral contenant de la clinoptilolite ou clinoptilolite destiné à être utilisé en tant que pansement pour plaie minéral

Publications (1)

Publication Number Publication Date
WO2025232973A1 true WO2025232973A1 (fr) 2025-11-13

Family

ID=91070133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/062770 Pending WO2025232973A1 (fr) 2024-05-08 2024-05-08 Mélange minéral contenant de la clinoptilolite ou clinoptilolite destiné à être utilisé en tant que pansement pour plaie minéral

Country Status (1)

Country Link
WO (1) WO2025232973A1 (fr)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1316530A1 (fr) * 1999-04-26 2003-06-04 Tihomir Lelas Zeolithes micronisées destinés à être utilisés comme préparations pharmaceutiques
WO2007090846A1 (fr) * 2006-02-09 2007-08-16 Durtec Gmbh Agents hémostatiques
EP2149375A1 (fr) * 2008-07-28 2010-02-03 Despharma Kft. Compositions pour le traitement de maladies dermatologiques et leurs utilisations
WO2010018418A1 (fr) * 2008-08-12 2010-02-18 Novatech D.O.O. Formulation à base de clinoptilolite micronisée utilisée en tant qu’agent thérapeutique produisant un silicium extrêmement biodisponible
WO2010057849A1 (fr) 2008-11-21 2010-05-27 Froximun Ag Procédé de réduction de la concentration des amines et de leurs sels
AT511961B1 (de) * 2011-11-15 2013-04-15 Ipus Mineral & Umwelttechnologie Gmbh Wässrige paste zur äusseren anwendung auf euter von milchproduzierenden nutztieren
DE102012010455A1 (de) * 2012-05-26 2013-12-19 Peter Brusek Mittel zur Pflege von Hautverletzungen und entzündlichen Hauterkrankungen bei Tieren
BG2002U1 (bg) * 2014-01-24 2014-12-30 БАЛКАНСКИ, Николай Средство за лечение на рани
RU2588968C1 (ru) * 2015-06-22 2016-07-10 Общество с ограниченной ответственностью "Биологические медицинские технологии" (ООО "БИОМЕДТЕХ") Состав для биологически активной гелевой повязки
WO2023152241A1 (fr) 2022-02-09 2023-08-17 Dietrich Seidel Colestyramine pour le traitement de plaies, d'infections bactériennes de la peau et de lésions cutanées inflammatoires

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1316530A1 (fr) * 1999-04-26 2003-06-04 Tihomir Lelas Zeolithes micronisées destinés à être utilisés comme préparations pharmaceutiques
WO2007090846A1 (fr) * 2006-02-09 2007-08-16 Durtec Gmbh Agents hémostatiques
EP2149375A1 (fr) * 2008-07-28 2010-02-03 Despharma Kft. Compositions pour le traitement de maladies dermatologiques et leurs utilisations
WO2010018418A1 (fr) * 2008-08-12 2010-02-18 Novatech D.O.O. Formulation à base de clinoptilolite micronisée utilisée en tant qu’agent thérapeutique produisant un silicium extrêmement biodisponible
WO2010057849A1 (fr) 2008-11-21 2010-05-27 Froximun Ag Procédé de réduction de la concentration des amines et de leurs sels
AT511961B1 (de) * 2011-11-15 2013-04-15 Ipus Mineral & Umwelttechnologie Gmbh Wässrige paste zur äusseren anwendung auf euter von milchproduzierenden nutztieren
DE102012010455A1 (de) * 2012-05-26 2013-12-19 Peter Brusek Mittel zur Pflege von Hautverletzungen und entzündlichen Hauterkrankungen bei Tieren
BG2002U1 (bg) * 2014-01-24 2014-12-30 БАЛКАНСКИ, Николай Средство за лечение на рани
RU2588968C1 (ru) * 2015-06-22 2016-07-10 Общество с ограниченной ответственностью "Биологические медицинские технологии" (ООО "БИОМЕДТЕХ") Состав для биологически активной гелевой повязки
WO2023152241A1 (fr) 2022-02-09 2023-08-17 Dietrich Seidel Colestyramine pour le traitement de plaies, d'infections bactériennes de la peau et de lésions cutanées inflammatoires

Similar Documents

Publication Publication Date Title
DE69923987T2 (de) Synergistische antimikrobielle, dermatologische und ophtahalmologische zubereitung, die ein chlorit und wasserstoffperoxid enthalten
EP2099462B1 (fr) Préparation pharmaceutique pour le traitement de pathologies inflammatoires du système urogénital
DE3750836T2 (de) Zwei-stufen-verfahren zur heilung schmerzenfreier wunden, sowie wässriges medium und topische salbe zur verwendung dazu.
EP2214658B1 (fr) Préparation contenant des osmolytes destinée à être employée en cas de muqueuses sèches
DE3856018T2 (de) Verwendung von einer Disaccharidpolysulfat-Aluminium Verbindung zur Herstellung eines Medikaments zur Behandlung von HÄMORRHOIDEN und zur Wundheilung
DE69629553T2 (de) Verfahren zur behandlung von interstitieller blasenentzündung mit hyaluronsäure
EP1455803A1 (fr) Composition pharmaceutique pour une utilisation ophtalmologique et rhinologique
US20140348775A1 (en) Wound treatment drug for external use
CH653892A5 (de) Wundheilmittel zur bedeckung von wunden und verbrennungen.
DE60027209T2 (de) Behandlung von Knochengewebserkrankungen
CH662945A5 (de) Ophthalmische loesung.
DE10337340A1 (de) Zusammensetzung
DE69421280T2 (de) Therapeutisches agens
DE2113215A1 (de) Therapeutisches Kompositum
DE3826419A1 (de) Die wundheilung foerderndes arzneimittelpraeparat und verfahren zu seiner herstellung
DE69105077T2 (de) Verwendung von Polysacchariden in Zubereitungen zur Wundbehandlung.
WO2025232973A1 (fr) Mélange minéral contenant de la clinoptilolite ou clinoptilolite destiné à être utilisé en tant que pansement pour plaie minéral
EP0668768B1 (fr) Composition permettant de lutter contre les dermatomycoses et leurs agents causals, ainsi que contre la sudation et les odeurs corporelles
DE60010886T2 (de) Extrakte, formulierung und verwendung von medikamenten aus blättern von cajanus cajan(l.) milsp.
DE102007002073A1 (de) Mittel zur Pflege und antimikrobiellen Behandlung der Haut
DE2412128A1 (de) Chirurgischer verband und verfahren zur bildung desselben in situ
EP1135116A1 (fr) Utilisation de poly (hexamethylene) biguanide pour produire un agent destine a favoriser la guerison de blessures non infectees
DE102015222429A1 (de) Biofilmbildendes Mittel zur leichteren Wundheilung und zum Abdecken und zum Schutz biologischer Organe
DE3818094C1 (fr)
DE60215219T2 (de) Verwendung von darifenacin zur behandlung des harndrangs